An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks

Speciality: Hematology


Speaker:

Prof. Dr. Christian Breymann | Specialist in Gynecology and Obstetrics, Perinatal Zurich

Description:

A warm welcome to all the medical professionals in this session, "An Eagle's View - Evidence-based discussion on Iron Deficiency Anemia." This discussion will provide a high-level, evidence-based overview of Iron Deficiency Anemia (IDA), the most common nutritional deficiency worldwide. Despite its prevalence, IDA is often underdiagnosed and undertreated, leading to significant health consequences. This session will offer a fresh perspective on the latest clinical data, moving beyond traditional approaches to focus on effective and patient-centered management strategies.

The discussion will explore the evidence supporting different therapeutic options, including oral iron supplementation and intravenous iron infusions. We'll delve into the specific patient populations that benefit most from each approach, such as those with intolerance to oral supplements, pregnant women, or patients with chronic conditions. Recent research has highlighted the improved safety and efficacy of modern intravenous iron formulations, making them a more viable and often preferred option for rapid iron replenishment and symptom relief. We will also address the challenges in diagnosis, particularly when inflammatory markers are elevated.

Therefore, get an overall knowledge of the evidence-based best practices in the diagnosis and treatment of iron deficiency anemia. Listen to the webinar, absorb the shared knowledge, and follow Hidoc for more such indispensable webinar sessions.


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Report reveals lung cancer is the leading cause of cancer deaths in Florida

2.

Prostate cancer early detection system eliminates need for biopsy.

3.

Infection tied to one-fourth of deaths with lower-risk myelodysplastic syndromes

4.

November 2023, Medical Bulletin 04/.

5.

For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot